As of 2026-04-05, the Relative Valuation of Zentalis Pharmaceuticals Inc (ZNTL) is (39.08) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.63 USD, the upside of Zentalis Pharmaceuticals Inc based on Relative Valuation is -1585.9%.
The range of the Relative Valuation is (35.85) - (40.71) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.9x - 22.7x | 20.4x |
| Forward P/E multiples | 18.0x - 21.5x | 20.8x |
| Fair Price | (35.85) - (40.71) | (39.08) |
| Upside | -1463.3% - -1647.9% | -1585.9% |
| Date | P/E |
| 2026-04-02 | -1.39 |
| 2026-04-01 | -1.35 |
| 2026-03-31 | -1.23 |
| 2026-03-30 | -1.13 |
| 2026-03-27 | -1.11 |
| 2026-03-26 | -1.41 |
| 2026-03-25 | -1.34 |
| 2026-03-24 | -1.30 |
| 2026-03-23 | -1.33 |
| 2026-03-20 | -1.38 |
| 2026-03-19 | -1.35 |
| 2026-03-18 | -1.33 |
| 2026-03-17 | -1.44 |
| 2026-03-16 | -1.43 |
| 2026-03-13 | -1.43 |
| 2026-03-12 | -1.45 |
| 2026-03-11 | -1.56 |
| 2026-03-10 | -1.61 |
| 2026-03-09 | -1.31 |
| 2026-03-06 | -1.21 |
| 2026-03-05 | -1.15 |
| 2026-03-04 | -1.32 |
| 2026-03-03 | -1.25 |
| 2026-03-02 | -1.32 |
| 2026-02-27 | -1.26 |
| 2026-02-26 | -1.30 |
| 2026-02-25 | -1.30 |
| 2026-02-24 | -1.30 |
| 2026-02-23 | -1.29 |
| 2026-02-20 | -1.28 |
| 2026-02-19 | -1.33 |
| 2026-02-18 | -1.27 |
| 2026-02-17 | -1.24 |
| 2026-02-13 | -1.26 |
| 2026-02-12 | -1.23 |
| 2026-02-11 | -1.28 |
| 2026-02-10 | -1.27 |
| 2026-02-09 | -1.27 |
| 2026-02-06 | -1.26 |
| 2026-02-05 | -1.16 |
| 2026-02-04 | -1.34 |
| 2026-02-03 | -1.49 |
| 2026-02-02 | -1.32 |
| 2026-01-30 | -1.28 |
| 2026-01-29 | -1.32 |
| 2026-01-28 | -1.35 |
| 2026-01-27 | -1.54 |
| 2026-01-26 | -1.48 |
| 2026-01-23 | -1.55 |
| 2026-01-22 | -1.71 |